Herbalife Posts 6.0% Sales Growth for Fifth Consecutive Quarter
Key Facts
Herbalife reported 6.0% growth in net sales in the third quarter of 2026, marking its fifth consecutive quarter of expansion, according to the headline of an earnings statement the company released on November 2. The growth was above the top end of its previous quarterly guidance, which ranged from 0.5% to 4.5% on a reported-dollar basis and from 1.5% to 5.5% on a constant-currency basis. The figure in the statement headline did not specify the basis used to calculate growth, so it cannot be attributed to either basis without further detail. Interim Chief Executive John DeSimone said, "Third-quarter results demonstrate continued progress, with strong sales and profitability growth and cash generation." The statement headline described profitability as strong and operating cash flow as robust, without giving a specific figure for either.
The figure extends a sequence of year-over-year growth that began five quarters ago, according to the company. In its second-quarter results, it said sales rose 5.4% year over year, or 5.8% excluding the impact of currency changes. That was the fourth consecutive quarter of growth, making the third-quarter announcement the fifth in the sequence. The company said foreign exchange reduced reported sales growth in the second quarter by 40 basis points. Sales for that quarter were $1,326.8 million, while first-half sales were $2,644.0 million, up 6.6% year over year. These figures provide a comparison with the prior period, while the third-quarter announcement headline does not state sales in dollars or the growth rate on a constant-currency basis.
The comparison base for the third quarter of last year was sales of $1,273.7 million, according to the guidance table published by the company. For fiscal 2025, Herbalife recorded actual sales of $5,037.5 million. On August 31, the company reaffirmed its 2026 annual sales growth forecast of 2.5% to 5.5%, on both a reported-dollar and constant-currency basis. That guidance followed a lower expected growth range for the third quarter, of 0.5% to 4.5% on a reported basis and 1.5% to 5.5% in constant currency. The reported third-quarter growth of 6.0% puts the result above the top end of both quarterly ranges, while the basis used for the published figure remains unspecified in the statement headline.
In its August guidance, the company also kept its 2026 adjusted EBITDA forecast at $670 million to $690 million on a reported basis and $690 million to $710 million on a constant-currency basis. In August, it had expressed confidence in delivering a fifth consecutive quarter of year-over-year sales growth and said its outlook for the rest of the year remained on track. Before the third-quarter results were announced, this annual guidance was the company's published framework for sales performance. The November 2 statement headline does not say whether Herbalife revised its annual forecast or adjusted EBITDA range after the results. Management is scheduled to discuss the results on an investor call on November 2 at 5:00 p.m. Eastern Time, after the results were announced following the close of trading on the New York Stock Exchange.
As part of its capital allocation, the board authorized in September the repurchase of up to $250 million of common stock over three years. The authorization sets a ceiling for the program but does not require the company to buy a specified number of shares. The company said the repurchase program may be suspended, modified or discontinued. The results announcement follows the reaffirmation of the annual sales range in August, while the scheduled management call offers an opportunity to present the figures and discuss financial guidance with investors. Annual sales growth is still expected at 2.5% to 5.5%, and adjusted EBITDA at $670 million to $690 million on a reported basis or $690 million to $710 million in constant currency, according to the latest published guidance in the available evidence.